Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations.

We sought to determine the prevalence of androgen receptor (AR) expression in a predominantly estrogen receptor (ER)-negative subset of breast cancers and delineate the immunohistochemical and clinical associations, including whether AR expression has prognostic significance in ER-negative tumors. We identified 69 ER-negative and 19 ER-positive breast cancer cases with concurrent immunohistochemical prognostic panels (ER, PR, HER-2/neu, Ki-67, and p53); immunohistochemical analysis was performed for AR using standard techniques. Clinical data were extracted from medical records. chi 2 tests were used to assess associations between variables. AR was found in 49% (34/69) of ER-negative and 89% (17/19) of ER-positive cases. In ER-negative tumors, AR was associated with increased age (P = .02), postmenopausal status (P < .001), tumor grade (P = .03), tumor size (P = .03), and HER-2/neu overexpression (P = .003). In ER-positive tumors, AR was associated with progesterone receptor expression (P < .03). In univariate analysis of ER-negative tumors, patients with AR-positive tumors had significantly better disease-free survival (P = .049). AR is expressed in a significant number of ER-negative cases and shows significant associations with important clinical and pathologic prognostic factors.

[1]  M. Aragno,et al.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[3]  M. Bryś,et al.  Androgen receptor status in female breast cancer: RT-PCR and Western blot studies , 2002, Journal of Cancer Research and Clinical Oncology.

[4]  B. Xie,et al.  The role of androgens in mammary carcinogenesis. , 2001, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

[5]  R A Irvine,et al.  Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. , 2000, Cancer research.

[6]  S. Tsao,et al.  Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. , 1999, Carcinogenesis.

[7]  S. Cummings,et al.  Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer , 1999, Annals of Internal Medicine.

[8]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[9]  Vessey Mp Effect of endogenous and exogenous hormones on breast cancer: epidemiology. , 1997 .

[10]  T. H. van der Kwast,et al.  The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. , 1996, European journal of cancer.

[11]  S. Hilsenbeck,et al.  Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Barnes,et al.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? , 1993, Human pathology.

[13]  J. Isola Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors , 1993, The Journal of pathology.

[14]  J. Varhaug,et al.  Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[16]  R. Bryan,et al.  Androgen receptors in breast cancer , 1984, Cancer.

[17]  F. Berrino,et al.  Increased androgenic activity and breast cancer risk in premenopausal women. , 1984, Cancer research.

[18]  J. Wittliff Steroid‐hormone receptors in breast cancer , 1984, Cancer.

[19]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[20]  E. J. Gregory,et al.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.